Neurogene Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
NGNE$25.28-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
NEUROGENE INC.
Index to Financial Statements
| Reports of Independent Registered Public Accounting Firms (PCAOB ID: 34 and 42) | 108 |
|---|---|
| Consolidated Balance Sheets | 112 |
| Consolidated Statements of Operations | 113 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit) | 114 |
| Consolidated Statements of Cash Flows | 115 |
| Notes to Consolidated Financial Statements | 116 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.